Pre-made Secukinumab benchmark antibody ( Whole mAb, anti-IL17A/IL17 therapeutic antibody, Anti-CTLA-8/CTLA8A/ILA17 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Secukinumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-510-1mg	1mg	3090
GMP-Bios-ab-510-10mg	10mg	Inquiry
GMP-Bios-ab-510-100mg	100mg	Inquiry
GMP-Bios-ab-510-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Secukinumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
INN Name	Secukinumab
Target	IL17
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	6wio:AB/6wir:AB
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Beth Israel Deaconess Medical Center;GWT-TUD GmbH;Icahn School of Medicine at Mount Sinai;Novartis;Alcon
Conditions Approved	Ankylosing spondylitis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions Active	Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Rheumatoid arthritis;Alopecia areata;Atopic dermatitis;Giant cell arteritis;Necrobiosis lipoidica;Tendon injuries
Conditions Discontinued	Asthma;Crohn's disease;Dry eyes;Multiple sclerosis;Polymyalgia rheumatica;Type 1 diabetes mellitus;Uveitis
Development Tech	Abgenix XenoMouse